Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Non Operating Income (2018 - 2025)

Historic Non Operating Income for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to $1.8 million.

  • Whitehawk Therapeutics' Non Operating Income rose 10761.25% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.8 million, marking a year-over-year increase of 194682.54%. This contributed to the annual value of $3.8 million for FY2024, which is 3892.67% down from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Non Operating Income of $1.8 million as of Q3 2025, which was up 10761.25% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Non Operating Income registered a high of $88.2 million during Q1 2025, and its lowest value of -$1.4 million during Q1 2021.
  • Its 5-year average for Non Operating Income is $5.5 million, with a median of $1.2 million in 2024.
  • Its Non Operating Income has fluctuated over the past 5 years, first soared by 1153576.72% in 2021, then tumbled by 9572.83% in 2022.
  • Over the past 5 years, Whitehawk Therapeutics' Non Operating Income (Quarter) stood at -$45000.0 in 2021, then soared by 3544.44% to $1.5 million in 2022, then dropped by 6.77% to $1.4 million in 2023, then tumbled by 53.22% to $676000.0 in 2024, then surged by 166.27% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $2.1 million for Q2 2025, and $88.2 million during Q1 2025.